Previous 10 | Next 10 |
The following slide deck was published by Aytu BioScience, Inc. in conjunction with this Read more ...
AIM ImmunoTech (NYSEMKT: AIM ) +34% after DoD grant for Ampligen in BMBC. More news on: AIM ImmunoTech Inc., Ideal Power Inc., New Age Beverages Corporation, Stocks on the move, Read more ...
During the 12-month period ending June 2019, the U.S. prescription TRT market registered 6.9 million prescriptions, generating approximately $1.7 billion in revenue ENGLEWOOD, CO / ACCESSWIRE / September 24, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company ...
ENGLEWOOD, CO / ACCESSWIRE / September 19, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that the company will present its operational results for the fiscal yea...
ENGLEWOOD, CO / ACCESSWIRE / September 17, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer, and David Green...
Acquisition Gives Aytu Timely Entry into Growing Consumer Healthcare Market with a Portfolio of Over 30 Products that Generated $24M of Revenue During Past Four Quarters Combination Will Create Specialty Rx and Consumer Pharma Company with Revenue of $31M New Products, Robus...
Androcryos, South Africa’s Largest Sperm Bank, First Laboratory in Africa to Offer MiOXSYS Test ENGLEWOOD, CO / ACCESSWIRE / September 10, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products address...
Co-promotion nearly doubles Tuzistra XR sales force Poly’s geographic footprint covers approximately 750,000 antitussive prescriptions annually accounting for approximately $128 million in annual revenue ENGLEWOOD, CO / ACCESSWIRE / September 4, 2019 / Aytu BioScience, Inc...
ZolpiMist Clinical Study Results Demonstrating Lingual Spray Delivers More Rapid Sleep Onset Compared to Tablet Form of Zolpidem Based on Efficacy Parameters and Pharmacokinetics ENGLEWOOD, CO / ACCESSWIRE / August 5, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty p...
Natesto Spermatogenesis Study Data Readout Set for October 16, 2019 ENGLEWOOD, CO / ACCESSWIRE / August 1, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs,...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...